{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:26:26Z","timestamp":1790483186293,"version":"4.1.0"},"reference-count":188,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"DOI":"10.13039\/501100001501","name":"UGC, University Grants Commission","doi-asserted-by":"publisher","award":["f.30-352\/2017"],"award-info":[{"award-number":["f.30-352\/2017"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"ICMR, Indian Council of Medical Research","doi-asserted-by":"publisher","award":["RBMH\/CAR 1312018-19"],"award-info":[{"award-number":["RBMH\/CAR 1312018-19"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"ICMR, Indian Council of Medical Research","doi-asserted-by":"publisher","award":["67\/9\/2020-DDI\/BMS"],"award-info":[{"award-number":["67\/9\/2020-DDI\/BMS"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Diabetes is a medical condition associated with impaired glucose regulation caused\neither due to insufficient insulin production or resistance to insulin (Type 2 diabetes, gestational\ndiabetes) or the absence of insulin through the selective killing of beta cells in the pancreas\n(Type 1 diabetes). Irregular insulin production leads to various health complications. To prevent\nsuch complications, patients must adhere to medical recommendations before availing of any\nadvanced insulin therapy(ies), considered productive for the treatment. Natural insulin, although\nhighly effective in controlling blood glucose levels, patients are often at risk of developing hypoglycemia\nand many other complications. This has led to the development of insulin analogs,\nthe modified variants of natural insulin having a minimal risk of causing hypoglycemia. Besides\nthe development of analogs, the mode of insulin delivery is also considered critical in achieving\nbetter glycemic control in diabetic patients. Until recently, various exogenous insulin delivery\nmethods were practiced, but effective glycemic control without any associated risk and ease of\ndelivery remains a subject of paramount concern. It countered attenuation or delayed onset of\ndiabetes-associated complications without a permanent cure, raising an unmet demand for insulin\nformulations and delivery methods that offer stability, biocompatibility, reproducibility, precision\ndosing, non-immunogenicity, and safety. The current practice utilizes non-physiological\ndelivery methods with less invasive administration routes, offering glycemic stability and therapeutic\neffectiveness. This review focuses on the recent advances made and future perspectives\nenvisioned about newer insulin therapies and delivery methods that tend to improve the management\nof diabetes by inculcating ideas to reduce the disease\u2019s severity and improve the quality\nof life.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113892010287216240324050651","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T05:12:40Z","timestamp":1712121160000},"page":"1050-1068","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges"],"prefix":"10.2174","volume":"26","author":[{"given":"Medha","family":"Bhagi","sequence":"first","affiliation":[{"name":"Centre for Molecular Biology, Central University of Jammu, UT of Jammu and Kashmir, 181143, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Kaur","sequence":"additional","affiliation":[{"name":"Centre for Molecular Biology, Central University of Jammu, UT of Jammu and Kashmir, 181143, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Dhar","sequence":"additional","affiliation":[{"name":"Department\nof Pharmacy, Birla Institute of Technology and Sciences Pilani, Hyderabad, Telangana, 500078, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2892-3910","authenticated-orcid":true,"given":"Audesh","family":"Bhat","sequence":"additional","affiliation":[{"name":"Centre for Molecular Biology, Central University of Jammu, UT of Jammu and Kashmir, 181143, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","year":"2021","unstructured":"IDF  Diabetes around the world in 2021  Available from:  https:\/\/www.diabetesatlas.org2021","journal-title":"IDF  Diabetes around the world in 2021"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"Davies M.J.","year":"2018","unstructured":"Davies M.J.; D\u2019Alessio D.A.; Fradkin J.; Kernan W.N.; Mathieu C.; Mingrone G.; Rossing P.; Tsapas A.; Wexler D.J.; Buse J.B.; Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care  2018,41(12),2669-2701","journal-title":"Diabetes Care"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/oxfordjournals.bmb.a069832","volume":"16","author":"Sanger F.","year":"1960","unstructured":"Sanger F.; Chemistry of insulin. Br Med Bull  1960,16(3),183-188","journal-title":"Br Med Bull"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/bcp.15100","volume":"88","author":"Seetharaman R.","year":"2022","unstructured":"Seetharaman R.; Pawar S.; Advani M.; One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. Br J Clin Pharmacol  2022,88(4),1598-1612","journal-title":"Br J Clin Pharmacol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12551-015-0186-2","volume":"8","author":"Navale A.M.","year":"2016","unstructured":"Navale A.M.; Paranjape A.N.; Glucose transporters: Physiological and pathological roles. Biophys Rev  2016,8(1),5-9","journal-title":"Biophys Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1152\/physrev.00008.2017","volume":"98","author":"Rorsman P.","year":"2018","unstructured":"Rorsman P.; Ashcroft F.M.; Pancreatic \u03b2-Cell electrical activity and insulin secretion: Of mice and men. Physiol Rev  2018,98(1),117-214","journal-title":"Physiol Rev"},{"key":"ref=7","author":"De Meyts P.","year":"2000","unstructured":"De Meyts P.;  The Insulin Receptor and Its Signal Transduction Network; Feingold, KR; Anawalt, B; Blackman, MR; Boyce, A; Chrousos, G  2000","journal-title":"The Insulin Receptor and Its Signal Transduction Network; Feingold, KR; Anawalt, B; Blackman, MR; Boyce, A; Chrousos, G"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1093\/clinchem\/48.12.2270","volume":"48","author":"Rosenfeld L.","year":"2002","unstructured":"Rosenfeld L.; Insulin: Discovery and Controversy. Clin Chem  2002,48(12),2270-2288","journal-title":"Clin Chem"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ijpharm.2018.06.023","volume":"547","author":"Akbarian M.","year":"2018","unstructured":"Akbarian M.; Ghasemi Y.; Uversky V.N.; Yousefi R.; Chemical modifications of insulin: Finding a compromise between stability and pharmaceutical performance. Int J Pharm  2018,547(1-2),450-468","journal-title":"Int J Pharm"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"108816","DOI":"10.1016\/j.diabres.2021.108816","volume":"175","author":"Home P.","year":"2021","unstructured":"Home P.; The evolution of insulin therapy. Diabetes Res Clin Pract  2021,175,108816","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=11","first-page":"239","volume":"35","author":"Rabinowitch I.M.","year":"1936","unstructured":"Rabinowitch I.M.; Foster J.S.; Fowler A.F.; Corcoran A.C.; Clinical experiences with protamine-zinc-insulin and other mixtures of zinc and insulin in diabetes mellitus. Can Med Assoc J  1936,35(3),239-252","journal-title":"Can Med Assoc J"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/333679a0","volume":"333","author":"Brange J.","year":"1988","unstructured":"Brange J.; Ribel U.; Hansen J.F.; Dodson G.; Hansen M.T.; Havelund S.; Melberg S.G.; Norris F.; Norris K.; Snel L.; S\u00f8rensen A.R.; Voigt H.O.; Monomeric insulins obtained by protein engineering and their medical implications. Nature  1988,333(6174),679-682","journal-title":"Nature"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.2337\/diab.37.3.276","volume":"37","author":"Fineberg S.E.","year":"1988","unstructured":"Fineberg S.E.; Rathbun M.J.; Hufferd S.; Fineberg N.S.; Spradlin C.T.; Galloway J.A.; Frank B.H.; Immunologic aspects of human proinsulin therapy. Diabetes  1988,37(3),276-280","journal-title":"Diabetes"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2337\/diabetes.49.6.999","volume":"49","author":"Kurtzhals P.","year":"2000","unstructured":"Kurtzhals P.; Sch\u00e4ffer L.; S\u00f8rensen A.; Kristensen C.; Jonassen I.; Schmid C.; Tr\u00fcb T.; Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes  2000,49(6),999-1005","journal-title":"Diabetes"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nbt0508-479","volume":"26","author":"Kling J.","year":"2008","unstructured":"Kling J.; Inhaled insulin\u2019s last gasp? Nat Biotechnol  2008,26(5),479-480","journal-title":"Nat Biotechnol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/1756-0500-5-214","volume":"5","author":"Tomas N.M.","year":"2012","unstructured":"Tomas N.M.; Masur K.; Piecha J.C.; Niggemann B.; Z\u00e4nker K.S.; Akt and phospholipase C\u03b3 are involved in the regulation of growth and migration of MDA-MB-468 breast cancer and SW480 colon cancer cells when cultured with diabetogenic levels of glucose and insulin. BMC Res Notes  2012,5(1),214","journal-title":"BMC Res Notes"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13046-015-0151-8","volume":"34","author":"Wei Z.","year":"2015","unstructured":"Wei Z.; Liang L.; Junsong L.; Rui C.; Shuai C.; Guanglin Q.; Shicai H.; Zexing W.; Jin W.; Xiangming C.; Shufeng W.; The impact of insulin on chemotherapeutic sensitivity to 5-fluorouracil in gastric cancer cell lines SGC7901, MKN45 and MKN28. J Exp Clin Cancer Res  2015,34(1),64","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.diabres.2010.11.009","volume":"91","author":"Liu S.","year":"2011","unstructured":"Liu S.; Li Y.; Lin T.; Fan X.; Liang Y.; Heemann U.; High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt. Diabetes Res Clin Pract  2011,91(2),177-182","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"e001346","DOI":"10.1136\/bmjdrc-2020-001346","volume":"8","author":"Wong C.K.H.","year":"2020","unstructured":"Wong C.K.H.; Man K.K.C.; Chan E.W.Y.; Wu T.; Tse E.T.Y.; Wong I.C.K.; Lam C.L.K.; DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin\u2013sulfonylurea dual therapy with inadequate control. BMJ Open Diabetes Res Care  2020,8(1),e001346","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3389\/fendo.2019.00443","volume":"10","author":"Tseng C.H.","year":"2019","unstructured":"Tseng C.H.; Human insulin therapy is associated with an increased risk of lung cancer: A population-based retrospective cohort study. Front Endocrinol (Lausanne)  2019,10,443","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/0090-4295(75)90344-1","volume":"5","author":"Dubroff L.M.","year":"1975","unstructured":"Dubroff L.M.; Duckett J.W.; Corriere J.N.; Phytohemagglutinin lymphocyte stimulation in children with recurrent urinary tract infections. Urology  1975,5(6),744-746","journal-title":"Urology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1097\/MJT.0000000000001076","volume":"27","author":"Cernea S.","year":"2020","unstructured":"Cernea S.; Raz I.; Insulin Therapy: Future Perspectives. Am J Ther  2020,27(1),e121-e132","journal-title":"Am J Ther"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"E886","DOI":"10.1152\/ajpendo.00608.2020","volume":"320","author":"Cheng R.","year":"2021","unstructured":"Cheng R.; Taleb N.; Stainforth-Dubois M.; Rabasa-Lhoret R.; The promising future of insulin therapy in diabetes mellitus. Am J Physiol Endocrinol Metab  2021,320(5),E886-E890","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1097\/MJT.0000000000001077","volume":"27","author":"Home P.","year":"2020","unstructured":"Home P.; Itzhak B.; Is Insulin Therapy Safe? Am J Ther  2020,27(1),e106-e114","journal-title":"Am J Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/biot.200700214","volume":"3","author":"Dingermann T.","year":"2008","unstructured":"Dingermann T.; Recombinant therapeutic proteins: Production platforms and challenges. Biotechnol J  2008,3(1),90-97","journal-title":"Biotechnol J"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1210\/endrev\/bnab020","volume":"42","author":"Rost\u00e8ne W.","year":"2021","unstructured":"Rost\u00e8ne W.; De Meyts P.; Insulin: A 100-Year-Old Discovery With a Fascinating History. Endocr Rev  2021,42(5),503-527","journal-title":"Endocr Rev"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/S2213-8587(15)00097-2","volume":"3","author":"Cahn A.","year":"2015","unstructured":"Cahn A.; Miccoli R.; Dardano A.; Del Prato S.; New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol  2015,3(8),638-652","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s13300-020-00831-z","volume":"11","author":"Kesavadev J.","year":"2020","unstructured":"Kesavadev J.; Saboo B.; Krishna M.B.; Krishnan G.; Evolution of insulin delivery devices: From syringes, pens, and pumps to diy artificial pancreas. Diabetes Ther  2020,11(6),1251-1269","journal-title":"Diabetes Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"11928","DOI":"10.1074\/jbc.RA118.002486","volume":"293","author":"Ong S.C.","year":"2018","unstructured":"Ong S.C.; Belgi A.; van Lierop B.; Delaine C.; Andrikopoulos S.; MacRaild C.A.; Norton R.S.; Haworth N.L.; Robinson A.J.; Forbes B.E.; Probing the correlation between insulin activity and structural stability through introduction of the rigid A6\u2013A11 bond. J Biol Chem  2018,293(30),11928-11943","journal-title":"J Biol Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2146\/ajhp110381","volume":"70","author":"Taylor J.R.","year":"2013","unstructured":"Taylor J.R.; Campbell K.M.; Insulin analogs for the management of type 2 diabetes. Am J Health Syst Pharm  2013,70(4),320-334","journal-title":"Am J Health Syst Pharm"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00125-008-0974-3","volume":"51","author":"Jeitler K.","year":"2008","unstructured":"Jeitler K.; Horvath K.; Berghold A.; Gratzer T.W.; Neeser K.; Pieber T.R.; Siebenhofer A.; Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: Systematic review and meta-analysis. Diabetologia  2008,51(6),941-951","journal-title":"Diabetologia"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1177\/1932296820928100","volume":"15","author":"Freckmann G.","year":"2021","unstructured":"Freckmann G.; Buck S.; Waldenmaier D.; Kulzer B.; Schnell O.; Gelchsheimer U.; Ziegler R.; Heinemann L.; Insulin pump therapy for patients with Type 2 Diabetes Mellitus: Evidence, current barriers, and new technologies. J Diabetes Sci Technol  2021,15(4),901-915","journal-title":"J Diabetes Sci Technol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11154-021-09635-3","volume":"22","author":"Boscari F.","year":"2021","unstructured":"Boscari F.; Avogaro A.; Current treatment options and challenges in patients with Type 1 diabetes: Pharmacological, technical advances and future perspectives. Rev Endocr Metab Disord  2021,22(2),217-240","journal-title":"Rev Endocr Metab Disord"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/193229681200600209","volume":"6","author":"Woods R.J.","year":"2012","unstructured":"Woods R.J.; Alarc\u00f3n J.; McVey E.; Pettis R.J.; Intrinsic fibrillation of fast-acting insulin analogs. J Diabetes Sci Technol  2012,6(2),265-276","journal-title":"J Diabetes Sci Technol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/dom.14355","volume":"23","author":"Boughton C.K.","year":"2021","unstructured":"Boughton C.K.; Hartnell S.; Thabit H.; Poettler T.; Herzig D.; Wilinska M.E.; Ashcroft N.L.; Sibayan J.; Cohen N.; Calhoun P.; Bally L.; Mader J.K.; Evans M.; Leelarathna L.; Hovorka R.; Hybrid closed\u2010loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double\u2010blind, multicentre, multinational, randomized, crossover study. Diabetes Obes Metab  2021,23(6),1389-1396","journal-title":"Diabetes Obes Metab"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1006\/jmbi.1996.0239","volume":"258","author":"Jacoby E.","year":"1996","unstructured":"Jacoby E.; Hua Q.X.; Stern A.S.; Frank B.H.; Weiss M.A.; Structure and dynamics of a protein assembly. 1H-NMR studies of the 36 kDa R6 insulin hexamer. J Mol Biol  1996,258(1),136-157","journal-title":"J Mol Biol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"50P","DOI":"10.1042\/bj1250050P","volume":"125","author":"Blundell T.L.","year":"1971","unstructured":"Blundell T.L.; Cutfield J.F.; Dodson G.G.; Dodson E.; Hodgkin D.C.; Mercola D.; The structure and biology of insulin. Biochem J  1971,125(3),50P-51P","journal-title":"Biochem J"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/261166a0","volume":"261","author":"Bentley G.","year":"1976","unstructured":"Bentley G.; Dodson E.; Dodson G.; Hodgkin D.; Mercola D.; Structure of insulin in 4-zinc insulin. Nature  1976,261(5556),166-168","journal-title":"Nature"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/338594a0","volume":"338","author":"Derewenda U.","year":"1989","unstructured":"Derewenda U.; Derewenda Z.; Dodson E.J.; Dodson G.G.; Reynolds C.D.; Smith G.D.; Sparks C.; Swenson D.; Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature  1989,338(6216),594-596","journal-title":"Nature"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1038\/s41598-021-81251-2","volume":"11","author":"Gillis R.B.","year":"2021","unstructured":"Gillis R.B.; Solomon H.V.; Govada L.; Oldham N.J.; Dinu V.; Jiwani S.I.; Gyasi-Antwi P.; Coffey F.; Meal A.; Morgan P.S.; Harding S.E.; Helliwell J.R.; Chayen N.E.; Adams G.G.; Analysis of insulin glulisine at the molecular level by X-ray crystallography and biophysical techniques. Sci Rep  2021,11(1),1737","journal-title":"Sci Rep"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc19-2550","volume":"43","author":"Blevins T.","year":"2020","unstructured":"Blevins T.; Zhang Q.; Frias J.P.; Jinnouchi H.; Chang A.M.; Randomized Double-Blind Clinical Trial Comparing Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes: PRONTO-T2D. Diabetes Care  2020,43(12),2991-2998","journal-title":"Diabetes Care"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s40262-020-00903-0","volume":"59","author":"Linnebjerg H.","year":"2020","unstructured":"Linnebjerg H.; Zhang Q.; LaBell E.; Dellva M.A.; Coutant D.E.; H\u00f6velmann U.; Plum-M\u00f6rschel L.; Herbrand T.; Leohr J.; Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog\u00ae (Lispro) in younger adults and elderly patients with Type 1 Diabetes Mellitus: A randomised controlled trial. Clin Pharmacokinet  2020,59(12),1589-1599","journal-title":"Clin Pharmacokinet"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/dom.13621","volume":"21","author":"Heise T.","year":"2019","unstructured":"Heise T.; Meiffren G.; Alluis B.; Seroussi C.; Ranson A.; Arrubla J.; Correia J.; Gaudier M.; Soula O.; Soula R.; DeVries J.H.; Klein O.; Bode B.; BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. Diabetes Obes Metab  2019,21(4),1066-1070","journal-title":"Diabetes Obes Metab"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"eaba6676","DOI":"10.1126\/scitranslmed.aba6676","volume":"12","author":"Mann J.L.","year":"2020","unstructured":"Mann J.L.; Maikawa C.L.; Smith A.A.A.; Grosskopf A.K.; Baker S.W.; Roth G.A.; Meis C.M.; Gale E.C.; Liong C.S.; Correa S.; Chan D.; Stapleton L.M.; Yu A.C.; Muir B.; Howard S.; Postma A.; Appel E.A.; An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients. Sci Transl Med  2020,12(550),eaba6676","journal-title":"Sci Transl Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"eabd6726","DOI":"10.1126\/scitranslmed.abd6726","volume":"13","author":"Maikawa C.L.","year":"2021","unstructured":"Maikawa C.L.; d\u2019Aquino A.I.; Lal R.A.; Buckingham B.A.; Appel E.A.; Engineering biopharmaceutical formulations to improve diabetes management. Sci Transl Med  2021,13(578),eabd6726","journal-title":"Sci Transl Med"},{"key":"ref=46","author":"Thota S.","year":"2023","unstructured":"Thota S.; Akbar A.;  Insulin  2023","journal-title":"Insulin"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1089\/dia.2020.0065","volume":"22","author":"Wilson L.M.","year":"2020","unstructured":"Wilson L.M.; Castle J.R.; Recent Advances in Insulin Therapy. Diabetes Technol Ther  2020,22(12),929-936","journal-title":"Diabetes Technol Ther"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","volume":"14","author":"Heise T.","year":"2012","unstructured":"Heise T.; Hermanski L.; Nosek L.; Feldman A.; Rasmussen S.; Haahr H.; Insulin degludec: Four times lower pharmacodynamic variability than insulin glargine under steady\u2010state conditions in type 1 diabetes. Diabetes Obes Metab  2012,14(9),859-864","journal-title":"Diabetes Obes Metab"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/dom.12032","volume":"15","author":"Ratner R.E.","year":"2013","unstructured":"Ratner R.E.; Gough S.C.L.; Mathieu C.; Del Prato S.; Bode B.; Mersebach H.; Endahl L.; Zinman B.; Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre\u2010planned meta\u2010analysis of phase 3 trials. Diabetes Obes Metab  2013,15(2),175-184","journal-title":"Diabetes Obes Metab"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/dom.12938","volume":"19","author":"Heise T.","year":"2017","unstructured":"Heise T.; N\u00f8rskov M.; Nosek L.; Kaplan K.; Famulla S.; Haahr H.L.; Insulin degludec: L ower day\u2010to\u2010day and within\u2010day variability in pharmacodynamic response compared with insulin glargine 300 U\/ML in type 1 diabetes. Diabetes Obes Metab  2017,19(7),1032-1039","journal-title":"Diabetes Obes Metab"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.12782","volume":"19","author":"Heise T.","year":"2017","unstructured":"Heise T.; Mathieu C.; Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab  2017,19(1),3-12","journal-title":"Diabetes Obes Metab"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.diabet.2017.10.001","volume":"44","author":"Bailey T.S.","year":"2018","unstructured":"Bailey T.S.; Pettus J.; Roussel R.; Schmider W.; Maroccia M.; Nassr N.; Klein O.; Bolli G.B.; Dahmen R.; Morning administration of 0.4 U\/kg\/day insulin glargine 300 U\/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U\/mL in type 1 diabetes. Diabetes Metab  2018,44(1),15-21","journal-title":"Diabetes Metab"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2337\/dc18-0559","volume":"41","author":"Rosenstock J.","year":"2018","unstructured":"Rosenstock J.; Cheng A.; Ritzel R.; Bosnyak Z.; Devisme C.; Cali A.M.G.; Sieber J.; Stella P.; Wang X.; Fr\u00edas J.P.; Roussel R.; Bolli G.B.; More similarities than differences testing insulin glargine 300 Units\/mL Versus insulin degludec 100 Units\/mL in insulin-naive Type 2 Diabetes: The randomized head-to-head BRIGHT trial. Diabetes Care  2018,41(10),2147-2154","journal-title":"Diabetes Care"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1177\/1932296819841585","volume":"13","author":"Philis-Tsimikas A.","year":"2019","unstructured":"Philis-Tsimikas A.; Stratton I.; N\u00f8rg\u00e5rd Troelsen L.; Anker Bak B.; Leiter L.A.; Efficacy and Safety of Degludec Compared to Glargine 300 Units\/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478). J Diabetes Sci Technol  2019,13(3),498-506","journal-title":"J Diabetes Sci Technol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s00125-019-05080-9","volume":"63","author":"Philis-Tsimikas A.","year":"2020","unstructured":"Philis-Tsimikas A.; Klonoff D.C.; Khunti K.; Bajaj H.S.; Leiter L.A.; Hansen M.V.; Troelsen L.N.; Ladelund S.; Heller S.; Pieber T.R.; Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: The randomised, head-to-head CONCLUDE trial. Diabetologia  2020,63(4),698-710","journal-title":"Diabetologia"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","volume":"10","author":"Heerspink H.J.L.","year":"2022","unstructured":"Heerspink H.J.L.; Sattar N.; Pavo I.; Haupt A.; Duffin K.L.; Yang Z.; Wiese R.J.; Tuttle K.R.; Cherney D.Z.I.; Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: Post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol  2022,10(11),774-785","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"Nathan D.M.","year":"2009","unstructured":"Nathan D.M.; Buse J.B.; Davidson M.B.; Ferrannini E.; Holman R.R.; Sherwin R.; Zinman B.; Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care  2009,32(1),193-203","journal-title":"Diabetes Care"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.17.S2.1","volume":"17","author":"Handelsman Y.","year":"2011","unstructured":"Handelsman Y.; Mechanick J.I.; Blonde L.; Grunberger G.; Bloomgarden Z.T.; Bray G.A.; Dagogo-Jack S.; Davidson J.A.; Einhorn D.; Ganda O.; Garber A.J.; Hirsch I.B.; Horton E.S.; Ismail-Beigi F.; Jellinger P.S.; Jones K.L.; Jovanovi\u010d L.; Lebovitz H.; Levy P.; Moghissi E.S.; Orzeck E.A.; Vinik A.I.; Wyne K.L.; Garber A.J.; Hurley D.L.; Zangeneh F.; American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract  2011,17(Suppl. 2),1-53","journal-title":"Endocr Pract"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1177\/193229681300700620","volume":"7","author":"Kerr D.","year":"2013","unstructured":"Kerr D.; Wizemann E.; Senstius J.; Zacho M.; Ampudia-Blasco F.J.; Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: A systematic review. J Diabetes Sci Technol  2013,7(6),1595-1606","journal-title":"J Diabetes Sci Technol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/BF00400425","volume":"39","author":"Ebeling P.","year":"1996","unstructured":"Ebeling P.; Tuominen J.A.; Koivisto V.A.; Insulin analogues and carcinoma of the breast. Diabetologia  1996,39(1),124-125","journal-title":"Diabetologia"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/13813455.2012.754474","volume":"119","author":"Tennagels N.","year":"2013","unstructured":"Tennagels N.; Werner U.; The metabolic and mitogenic properties of basal insulin analogues. Arch Physiol Biochem  2013,119(1),1-14","journal-title":"Arch Physiol Biochem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.2337\/db12-1773","volume":"62","author":"Varewijck A.J.","year":"2013","unstructured":"Varewijck A.J.; Yki-J\u00e4rvinen H.; Schmidt R.; Tennagels N.; Janssen J.A.M.J.L.; Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling. Diabetes  2013,62(7),2539-2544","journal-title":"Diabetes"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/413782","volume":"2012","author":"Hsieh M.C.","year":"2012","unstructured":"Hsieh M.C.; Lee T.C.; Cheng S.M.; Tu S.T.; Yen M.H.; Tseng C.H.; The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res  2012,2012,1-6","journal-title":"Exp Diabetes Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","volume":"52","author":"Currie C.J.","year":"2009","unstructured":"Currie C.J.; Poole C.D.; Gale E.A.M.; The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia  2009,52(9),1766-1777","journal-title":"Diabetologia"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s11892-013-0366-z","volume":"13","author":"Hanefeld M.","year":"2013","unstructured":"Hanefeld M.; Bramlage P.; Insulin use early in the course of type 2 diabetes mellitus: The ORIGIN trial. Curr Diab Rep  2013,13(3),342-349","journal-title":"Curr Diab Rep"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.2337\/db09-9030","volume":"58","author":"Butler P.C.","year":"2009","unstructured":"Butler P.C.; Insulin glargine controversy: A tribute to the editorial team at Diabetologia. Diabetes  2009,58(11),2427-2428","journal-title":"Diabetes"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2337\/diacare.29.02.06.dc05-1558","volume":"29","author":"Bowker S.L.","year":"2006","unstructured":"Bowker S.L.; Majumdar S.R.; Veugelers P.; Johnson J.A.; Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care  2006,29(2),254-258","journal-title":"Diabetes Care"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/j.gastro.2004.07.011","volume":"127","author":"Yang Y.X.","year":"2004","unstructured":"Yang Y.X.; Hennessy S.; Lewis J.D.; Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology  2004,127(4),1044-1050","journal-title":"Gastroenterology"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","volume":"330","author":"Evans J.M.M.","year":"2005","unstructured":"Evans J.M.M.; Donnelly L.A.; Emslie-Smith A.M.; Alessi D.R.; Morris A.D.; Metformin and reduced risk of cancer in diabetic patients. BMJ  2005,330(7503),1304-1305","journal-title":"BMJ"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1615692","volume":"377","author":"Marso S.P.","year":"2017","unstructured":"Marso S.P.; McGuire D.K.; Zinman B.; Poulter N.R.; Emerson S.S.; Pieber T.R.; Pratley R.E.; Haahr P.M.; Lange M.; Brown-Frandsen K.; Moses A.; Skibsted S.; Kvist K.; Buse J.B.; Efficacy and safety of degludec versus glargine in Type 2 Diabetes. N Engl J Med  2017,377(8),723-732","journal-title":"N Engl J Med"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/193229681000400113","volume":"4","author":"Senesh G.","year":"2010","unstructured":"Senesh G.; Bushi D.; Neta A.; Yodfat O.; Compatibility of insulin Lispro, Aspart, and Glulisine with the Solo MicroPump, a novel miniature insulin pump. J Diabetes Sci Technol  2010,4(1),104-110","journal-title":"J Diabetes Sci Technol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/8755122518802268","volume":"35","author":"White J.","year":"2019","unstructured":"White J.; Goldman J.; Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability. J Pharm Technol  2019,35(1),25-35","journal-title":"J Pharm Technol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1038\/sj.ijo.0802747","volume":"28","author":"Russell-Jones D.","year":"2004","unstructured":"Russell-Jones D.; Insulin detemir: Improving the predictability of glycaemic control. Int J Obes  2004,28(S2)(Suppl. 2),S29-S34","journal-title":"Int J Obes"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"237-OR","DOI":"10.2337\/db20-237-OR","volume":"69","author":"H\u00f6velmann U.","year":"2020","unstructured":"H\u00f6velmann U.; Br\u00f8ndsted L.; Kristensen N.R.; Ribel-Madsen R.; Devries J.H.; Heise T.; Haahr H.; 237-OR: Insulin Icodec: An Insulin Analog Suited for Once-Weekly Dosing in Type 2 Diabetes. Diabetes  2020,69(Suppl. 1),237-OR","journal-title":"Diabetes"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"Lau J.","year":"2015","unstructured":"Lau J.; Bloch P.; Sch\u00e4ffer L.; Pettersson I.; Spetzler J.; Kofoed J.; Madsen K.; Knudsen L.B.; McGuire J.; Steensgaard D.B.; Strauss H.M.; Gram D.X.; Knudsen S.M.; Nielsen F.S.; Thygesen P.; Reedtz-Runge S.; Kruse T.; Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1). Analogue Semaglutide J Med Chem  2015,58(18),7370-7380","journal-title":"Analogue Semaglutide J Med Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/cmdc.201700781","volume":"13","author":"Cheang J.Y.","year":"2018","unstructured":"Cheang J.Y.; Moyle P.M.; Glucagon\u2010Like Peptide\u20101 (GLP\u20101)\u2010Based Therapeutics: Current status and future opportunities beyond type 2 diabetes. ChemMedChem  2018,13(7),662-671","journal-title":"ChemMedChem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","volume":"9","author":"Nauck M.A.","year":"2021","unstructured":"Nauck M.A.; Wefers J.; Meier J.J.; Treatment of type 2 diabetes: Challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol  2021,9(8),525-544","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1021\/acs.jmedchem.0c01576","volume":"64","author":"Kjeldsen T.B.","year":"2021","unstructured":"Kjeldsen T.B.; Hub\u00e1lek F.; Tagmose T.M.; Pridal L.; Refsgaard H.H.F.; Porsgaard T.; Gram-Nielsen S.; Hovgaard L.; Valore H.; M\u00fcnzel M.; Hj\u00f8rringgaard C.U.; Jeppesen C.B.; Manf\u00e8 V.; Hoeg-Jensen T.; Ludvigsen S.; Nielsen P.K.; Lautrup-Larsen I.; Stidsen C.E.; Wulff E.M.; Garibay P.W.; Kodra J.T.; Nishimura E.; Madsen P.; Engineering of orally available, ultralong-acting insulin analogues: Discovery of OI338 and OI320. J Med Chem  2021,64(1),616-628","journal-title":"J Med Chem"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"236-OR","DOI":"10.2337\/db20-236-OR","volume":"69","author":"Nishimura E.","year":"2020","unstructured":"Nishimura E.; Kjeldsen T.; Hubalek F.; Glendorf T.; Stidsen C.; Hansen B.F.; Pedersen T.A.; Luetzen A.; Pridal L.; Madsen P.; 236-OR: Molecular and Biological Properties of Insulin Icodec, a New Insulin Analog Designed to Give a Long Half-Life Suitable for Once-Weekly Dosing. Diabetes  2020,69(Suppl. 1),236-OR","journal-title":"Diabetes"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.2337\/dc20-2877","volume":"44","author":"Bajaj H.S.","year":"2021","unstructured":"Bajaj H.S.; Bergenstal R.M.; Christoffersen A.; Davies M.J.; Gowda A.; Isendahl J.; Lingvay I.; Senior P.A.; Silver R.J.; Trevisan R.; Rosenstock J.; Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in Type 2 Diabetes inadequately controlled on daily basal insulin: A phase 2 randomized controlled trial. Diabetes Care  2021,44(7),1586-1594","journal-title":"Diabetes Care"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1056\/NEJMoa2022474","volume":"383","author":"Rosenstock J.","year":"2020","unstructured":"Rosenstock J.; Bajaj H.S.; Jane\u017e A.; Silver R.; Begtrup K.; Hansen M.V.; Jia T.; Goldenberg R.; Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med  2020,383(22),2107-2116","journal-title":"N Engl J Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1800458","DOI":"10.1002\/mabi.201800458","volume":"19","author":"Baghban Taraghdari Z.","year":"2019","unstructured":"Baghban Taraghdari Z.; Imani R.; Mohabatpour F.; A Review on Bioengineering Approaches to Insulin Delivery: A Pharmaceutical and Engineering Perspective. Macromol Biosci  2019,19(4),1800458","journal-title":"Macromol Biosci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"494","DOI":"10.2337\/db13-0826","volume":"63","author":"Moore M.C.","year":"2014","unstructured":"Moore M.C.; Smith M.S.; Sinha V.P.; Beals J.M.; Michael M.D.; Jacober S.J.; Cherrington A.D.; Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes  2014,63(2),494-504","journal-title":"Diabetes"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/dom.12222","volume":"16","author":"Sinha V.P.","year":"2014","unstructured":"Sinha V.P.; Howey D.C.; Choi S.L.; Mace K.F.; Heise T.; Steady\u2010state pharmacokinetics and glucodynamics of the novel, long\u2010acting basal insulin LY2605541 dosed once\u2010daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab  2014,16(4),344-350","journal-title":"Diabetes Obes Metab"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/13543784.2017.1274732","volume":"26","author":"Hedrington M.S.","year":"2017","unstructured":"Hedrington M.S.; Davis S.N.; Discontinued drug therapies to treat diabetes in 2015. Expert Opin Investig Drugs  2017,26(2),219-225","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s13340-016-0255-1","volume":"7","author":"Hirose T.","year":"2016","unstructured":"Hirose T.; Development of new basal insulin peglispro (LY2605541) ends in a disappointing result. Diabetol Int  2016,7(1),16-17","journal-title":"Diabetol Int"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"A329","DOI":"10.1210\/jendso\/bvab048.672","volume":"5","author":"Heise T.","year":"2021","unstructured":"Heise T.; Chien J.; Beals J.; Benson C.; Klein O.; Moyers, JS Basal Insulin Fc (BIF), a novel insulin suited for once weekly dosing for the treatment of patients with diabetes mellitus. J Endocr Soc  2021,5(1),A329","journal-title":"J Endocr Soc"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1124\/jpet.122.001105","volume":"382","author":"Moyers J.S.","year":"2022","unstructured":"Moyers J.S.; Hansen R.J.; Day J.W.; Dickinson C.D.; Zhang C.; Ruan X.; Ding L.; Brown R.M.; Baker H.E.; Beals J.M.; Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein. J Pharmacol Exp Ther  2022,382(3),346-355","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/dom.12485","volume":"17","author":"Ritzel R.","year":"2015","unstructured":"Ritzel R.; Roussel R.; Bolli G.B.; Vinet L.; Brulle-Wohlhueter C.; Glezer S.; Yki-J\u00e4rvinen H.; Patient\u2010level meta\u2010analysis of the EDITION 1, 2 and 3 studies: Glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus glargine 100 U\/ml in people with type 2 diabetes. Diabetes Obes Metab  2015,17(9),859-867","journal-title":"Diabetes Obes Metab"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2017.7117","volume":"318","author":"Wysham C.","year":"2017","unstructured":"Wysham C.; Bhargava A.; Chaykin L.; de la Rosa R.; Handelsman Y.; Troelsen L.N.; Kvist K.; Norwood P.; Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with Type 2 Diabetes. JAMA  2017,318(1),45-56","journal-title":"JAMA"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1746-1596-9-130","volume":"9","author":"Zhao C.","year":"2014","unstructured":"Zhao C.; Wang W.; Xu D.; Li H.; Li M.; Wang F.; Insulin and risk of diabetic retinopathy in patients with type 2 diabetes mellitus: Data from a meta-analysis of seven cohort studies. Diagn Pathol  2014,9(1),130","journal-title":"Diagn Pathol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1056\/NEJM198408093110604","volume":"311","year":"1984","unstructured":"Kroc Collaborative Study Group Blood glucose control and the evolution of diabetic retinopathy and albuminuria. A preliminary multicenter trial. N Engl J Med  1984,311(6),365-372","journal-title":"N Engl J Med"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.amjcard.2009.02.046","volume":"104","author":"Pop-Busui R.","year":"2009","unstructured":"Pop-Busui R.; Lombardero M.; Lavis V.; Forker A.; Green J.; Korytkowski M.; Sobel B.E.; Jones T.L.Z.; Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). Am J Cardiol  2009,104(1),52-58","journal-title":"Am J Cardiol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s00125-009-1415-7","volume":"52","author":"Rosenstock J.","year":"2009","unstructured":"Rosenstock J.; Fonseca V.; McGill J.B.; Riddle M.; Hall\u00e9 J.P.; Hramiak I.; Johnston P.; Davis M.; Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: A long-term, randomised, open-label study. Diabetologia  2009,52(9),1778-1788","journal-title":"Diabetologia"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1007\/s00125-010-1697-9","volume":"53","author":"Rasmussen K.L.","year":"2010","unstructured":"Rasmussen K.L.; Laugesen C.S.; Ringholm L.; Vestgaard M.; Damm P.; Mathiesen E.R.; Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia  2010,53(6),1076-1083","journal-title":"Diabetologia"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2337\/diaspect.29.2.92","volume":"29","author":"Blum A.K.","year":"2016","unstructured":"Blum A.K.; Insulin Use in Pregnancy: An Update. Diabetes Spectr  2016,29(2),92-97","journal-title":"Diabetes Spectr"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/17425255.2019.1585427","volume":"15","author":"Rendell M.","year":"2019","unstructured":"Rendell M.; Premix insulins in type 1 diabetes: The coming of degludec\/aspart. Expert Opin Drug Metab Toxicol  2019,15(4),341-348","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.diabres.2018.10.024","volume":"147","author":"Philis-Tsimikas A.","year":"2019","unstructured":"Philis-Tsimikas A.; Astamirova K.; Gupta Y.; Haggag A.; Roula D.; Bak B.A.; Fita E.G.; Nielsen A.M.; Demir T.; Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus. Diabetes Res Clin Pract  2019,147,157-165","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/dom.12097","volume":"15","author":"Onishi Y.","year":"2013","unstructured":"Onishi Y.; Ono Y.; Rab\u00f8l R.; Endahl L.; Nakamura S.; Superior glycaemic control with once\u2010daily insulin degludec\/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: A randomized, controlled phase 3 trial. Diabetes Obes Metab  2013,15(9),826-832","journal-title":"Diabetes Obes Metab"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2337\/dc10-1905","volume":"34","author":"Heise T.","year":"2011","unstructured":"Heise T.; Tack C.J.; Cuddihy R.; Davidson J.; Gouet D.; Liebl A.; Romero E.; Mersebach H.; Dykiel P.; Jorde R.; A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: A randomized, controlled trial. Diabetes Care  2011,34(3),669-674","journal-title":"Diabetes Care"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1530\/EJE-12-0293","volume":"167","author":"Niskanen L.","year":"2012","unstructured":"Niskanen L.; Leiter L.A.; Franek E.; Weng J.; Damci T.; Mu\u00f1oz-Torres M.; Donnet J.P.; Endahl L.; Skj\u00f8th T.V.; Vaag A.; Comparison of a soluble co-formulation of insulin degludec\/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: A randomised trial. Eur J Endocrinol  2012,167(2),287-294","journal-title":"Eur J Endocrinol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.2337\/dc11-2503","volume":"35","author":"Hirsch I.B.","year":"2012","unstructured":"Hirsch I.B.; Bode B.; Courreges J.P.; Dykiel P.; Franek E.; Hermansen K.; King A.; Mersebach H.; Davies M.; Insulin degludec\/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care  2012,35(11),2174-2181","journal-title":"Diabetes Care"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/dom.12609","volume":"18","author":"Rodbard H.W.","year":"2016","unstructured":"Rodbard H.W.; Cariou B.; Pieber T.R.; Endahl L.A.; Zacho J.; Cooper J.G.; Treatment intensification with an insulin degludec (IDEG)\/insulin aspart (IASP) co\u2010formulation twice daily compared with basal IDEG and prandial IASP in type 2 diabetes: A randomized, controlled phase III trial. Diabetes Obes Metab  2016,18(3),274-280","journal-title":"Diabetes Obes Metab"},{"key":"ref=104","volume":"10","author":"Kesavadev J.","year":"2022","unstructured":"Kesavadev J.; Gowda A.; Kumar H.; Yalamanchi S.R.; Lodha S.; Singh K.P.; Safety of Insulin Degludec\/Insulin Aspart in Patients with Diabetes Mellitus over a Period of 1 Year during Routine Clinical Care in India: SMART (Study of Management of Diabetes with Ryzodegandtrade; Treatment). Med Sci  2022,10(1)","journal-title":"Med Sci"},{"key":"ref=105","year":"2012","unstructured":"Novo Nordisk Company Announcement Ryzodeg\u00ae (insulin degludec\/insulin aspart) approved in Japan  Available from:  https:\/\/www.europeanpharmaceuticalreview.com\/news\/16275\/ryzodeg-insulin-degludecinsulin-aspart-approved-in-japan\/2012","journal-title":"Novo Nordisk Company Announcement Ryzodeg\u00ae (insulin degludec\/insulin aspart) approved in Japan"},{"key":"ref=106","year":"2015","unstructured":"Fierce Biotech FDA Approves Two New Drug Treatments for Diabetes Mellitus  Available from:  https:\/\/www.fiercebiotech.com\/biotech\/fda-accepts-sanofi-new-drug-application-for-once-daily-fixed-ratio-combination-of-insulin2015","journal-title":"Fierce Biotech FDA Approves Two New Drug Treatments for Diabetes Mellitus"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1177\/0018578717715383","volume":"52","author":"Baker D.E.","year":"2017","unstructured":"Baker D.E.; Insulin Degludec\/Liraglutide. Hosp Pharm  2017,52(5),374-380","journal-title":"Hosp Pharm"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1111\/dom.15027","volume":"25","author":"Guja C.","year":"2023","unstructured":"Guja C.; Kis J.T.; Haluz\u00edk M.; Bonnemaire M.; Bigot G.; Tournay M.; Freemantle N.; Seufert J.; IGLARLIXI (insulin glargine 100 U\/ML plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real\u2010world data. Diabetes Obes Metab  2023,25(6),1723-1730","journal-title":"Diabetes Obes Metab"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12902-023-01282-w","volume":"23","author":"Risovic I.","year":"2023","unstructured":"Risovic I.; Dumanovic M.S.; Bojic M.; Djekic D.; Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes. BMC Endocr Disord  2023,23(1),28","journal-title":"BMC Endocr Disord"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"101107","DOI":"10.1016\/j.molmet.2020.101107","volume":"46","author":"Hoeg-Jensen T.","year":"2021","unstructured":"Hoeg-Jensen T.; Review: Glucose-sensitive insulin. Mol Metab  2021,46,101107","journal-title":"Mol Metab"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2337\/db17-0577","volume":"67","author":"Kaarsholm N.C.","year":"2018","unstructured":"Kaarsholm N.C.; Lin S.; Yan L.; Kelly T.; van Heek M.; Mu J.; Wu M.; Dai G.; Cui Y.; Zhu Y.; Carballo-Jane E.; Reddy V.; Zafian P.; Huo P.; Shi S.; Antochshuk V.; Ogawa A.; Liu F.; Souza S.C.; Seghezzi W.; Duffy J.L.; Erion M.; Nargund R.P.; Kelley D.E.; Engineering Glucose Responsiveness Into Insulin. Diabetes  2018,67(2),299-308","journal-title":"Diabetes"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2337\/db18-0099","volume":"67","author":"Moore M.C.","year":"2018","unstructured":"Moore M.C.; Kelley D.E.; Camacho R.C.; Zafian P.; Ye T.; Lin S.; Kaarsholm N.C.; Nargund R.; Kelly T.M.; Van Heek M.; Previs S.F.; Moyes C.; Smith M.S.; Farmer B.; Williams P.; Cherrington A.D.; Superior Glycemic Control With a Glucose-Responsive Insulin Analog: Hepatic and Nonhepatic Impacts. Diabetes  2018,67(6),1173-1181","journal-title":"Diabetes"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"e97476","DOI":"10.1172\/jci.insight.97476","volume":"3","author":"Yang R.","year":"2018","unstructured":"Yang R.; Wu M.; Lin S.; Nargund R.P.; Li X.; Kelly T.; Yan L.; Dai G.; Qian Y.; Dallas-yang Q.; Fischer P.A.; Cui Y.; Shen X.; Huo P.; Feng D.D.; Erion M.D.; Kelley D.E.; Mu J.; A glucose-responsive insulin therapy protects animals against hypoglycemia. JCI Insight  2018,3(1),e97476","journal-title":"JCI Insight"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1002\/cpt.1729","volume":"107","author":"Visser S.A.G.","year":"2020","unstructured":"Visser S.A.G.; Kandala B.; Fancourt C.; Krug A.W.; Cho C.R.; A Model\u2010Informed Drug Discovery and Development Strategy for the Novel Glucose\u2010Responsive Insulin MK\u20102640 Enabled Rapid Decision Making. Clin Pharmacol Ther  2020,107(6),1296-1311","journal-title":"Clin Pharmacol Ther"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1021\/acschembio.9b00420","volume":"14","author":"Brunel F.M.","year":"2019","unstructured":"Brunel F.M.; Mayer J.P.; Gelfanov V.M.; Zaykov A.N.; Finan B.; Perez-Tilve D.; DiMarchi R.D.; A Disulfide Scan of Insulin by [3 + 1] Methodology Exhibits Site-Specific Influence on Bioactivity. ACS Chem Biol  2019,14(8),1829-1835","journal-title":"ACS Chem Biol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1021\/ja051038k","volume":"127","author":"Hoeg-Jensen T.","year":"2005","unstructured":"Hoeg-Jensen T.; Havelund S.; Nielsen P.K.; Markussen J.; Reversible insulin self-assembly under carbohydrate control. J Am Chem Soc  2005,127(17),6158-6159","journal-title":"J Am Chem Soc"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1039\/C9CS00391F","volume":"49","author":"Davis A.P.","year":"2020","unstructured":"Davis A.P.; Biomimetic carbohydrate recognition. Chem Soc Rev  2020,49(9),2531-2545","journal-title":"Chem Soc Rev"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/2230-973X.176456","volume":"6","author":"Shah R.","year":"2016","unstructured":"Shah R.; Shah V.N.; Patel M.; Maahs D.M.; Insulin delivery methods: Past, present and future. Int J Pharm Investig  2016,6(1),1-9","journal-title":"Int J Pharm Investig"},{"key":"ref=119","first-page":"73","volume":"5","author":"Gualandi-Signorini A.M.","year":"2001","unstructured":"Gualandi-Signorini A.M.; Giorgi G.; Insulin formulations-a review. Eur Rev Med Pharmacol Sci  2001,5(3),73-83","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1021\/acsnano.7b08152","volume":"12","author":"Wang J.","year":"2018","unstructured":"Wang J.; Ye Y.; Yu J.; Kahkoska A.R.; Zhang X.; Wang C.; Sun W.; Corder R.D.; Chen Z.; Khan S.A.; Buse J.B.; Gu Z.; Core\u2013Shell Microneedle Gel for Self-Regulated Insulin Delivery. ACS Nano  2018,12(3),2466-2473","journal-title":"ACS Nano"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/jbm.a.35869","volume":"105","author":"Lee I.C.","year":"2017","unstructured":"Lee I.C.; Lin W.M.; Shu J.C.; Tsai S.W.; Chen C.H.; Tsai M.T.; Formulation of two\u2010layer dissolving polymeric microneedle patches for insulin transdermal delivery in diabetic mice. J Biomed Mater Res A  2017,105(1),84-93","journal-title":"J Biomed Mater Res A"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.3390\/ma11091625","volume":"11","author":"Chen C.H.","year":"2018","unstructured":"Chen C.H.; Shyu V.; Chen C.T.; Dissolving Microneedle Patches for Transdermal Insulin Delivery in Diabetic Mice: Potential for Clinical Applications. Materials (Basel)  2018,11(9),1625","journal-title":"Materials (Basel)"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41378-020-00224-z","volume":"6","author":"Yang J.","year":"2020","unstructured":"Yang J.; Li Y.; Ye R.; Zheng Y.; Li X.; Chen Y.; Xie X.; Jiang L.; Smartphone-powered iontophoresis-microneedle array patch for controlled transdermal delivery. Microsyst Nanoeng  2020,6(1),112","journal-title":"Microsyst Nanoeng"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.2042-7158.2011.01369.x","volume":"64","author":"Bariya S.H.","year":"2011","unstructured":"Bariya S.H.; Gohel M.C.; Mehta T.A.; Sharma O.P.; Microneedles: An emerging transdermal drug delivery system. J Pharm Pharmacol  2011,64(1),11-29","journal-title":"J Pharm Pharmacol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2337\/dc11-2054","volume":"35","author":"McCoy R.G.","year":"2012","unstructured":"McCoy R.G.; Van Houten H.K.; Ziegenfuss J.Y.; Shah N.D.; Wermers R.A.; Smith S.A.; Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care  2012,35(9),1897-1901","journal-title":"Diabetes Care"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/jdi.13372","volume":"12","author":"Basta G.","year":"2021","unstructured":"Basta G.; Montanucci P.; Calafiore R.; Microencapsulation of cells and molecular therapy of type 1 diabetes mellitus: The actual state and future perspectives between promise and progress. J Diabetes Investig  2021,12(3),301-309","journal-title":"J Diabetes Investig"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/965804","volume":"2015","author":"Montanucci P.","year":"2015","unstructured":"Montanucci P.; Terenzi S.; Santi C.; Pennoni I.; Bini V.; Pescara T.; Basta G.; Calafiore R.; Insights in Behavior of Variably Formulated Alginate-Based Microcapsules for Cell Transplantation. BioMed Res Int  2015,2015,1-11","journal-title":"BioMed Res Int"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41427-022-00385-5","volume":"14","author":"Liu X.","year":"2022","unstructured":"Liu X.; Yu Y.; Liu D.; Li J.; Sun J.; Wei Q.; Zhao Y.; Pandol S.J.; Li L.; Porous microcapsules encapsulating \u03b2 cells generated by microfluidic electrospray technology for diabetes treatment. NPG Asia Mater  2022,14(1),39","journal-title":"NPG Asia Mater"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1104979","DOI":"10.3389\/fchem.2022.1104979","volume":"10","author":"Luo Z.","year":"2023","unstructured":"Luo Z.; Dong Y.; Yu M.; Fu X.; Qiu Y.; Sun X.; Chu X.; A novel insulin delivery system by \u03b2 cells encapsulated in microcapsules. Front Chem  2023,10,1104979","journal-title":"Front Chem"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"110759","DOI":"10.1016\/j.colsurfb.2019.110759","volume":"188","author":"Stagnoli S.","year":"2020","unstructured":"Stagnoli S.; Sosa Alderete L.; Luna M.A.; Agostini E.; Falcone R.D.; Niebylski A.M.; Correa N.M.; Catanionic nanocarriers as a potential vehicle for insulin delivery. Colloids Surf B Biointerfaces  2020,188,110759","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2337\/dc11-1107","volume":"35","author":"Russell-Jones D.","year":"2012","unstructured":"Russell-Jones D.; Cuddihy R.M.; Hanefeld M.; Kumar A.; Gonz\u00e1lez J.G.; Chan M.; Wolka A.M.; Boardman M.K.; Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study. Diabetes Care  2012,35(2),252-258","journal-title":"Diabetes Care"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/10837450.2019.1619183","volume":"24","author":"Al-Nemrawi N.K.","year":"2019","unstructured":"Al-Nemrawi N.K.; Alsharif S.S.M.; Alzoubi K.H.; Alkhatib R.Q.; Preparation and characterization of insulin chitosan-nanoparticles loaded in buccal films. Pharm Dev Technol  2019,24(8),967-974","journal-title":"Pharm Dev Technol"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1208\/s12249-017-0725-1","volume":"18","author":"Kondiah P.P.D.","year":"2017","unstructured":"Kondiah P.P.D.; Choonara Y.E.; Tomar L.K.; Tyagi C.; Kumar P.; du Toit L.C.; Marimuthu T.; Modi G.; Pillay V.; Development of a Gastric Absorptive, Immediate Responsive, Oral Protein-Loaded Versatile Polymeric Delivery System. AAPS PharmSciTech  2017,18(7),2479-2493","journal-title":"AAPS PharmSciTech"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jconrel.2015.12.036","volume":"224","author":"Chou H.S.","year":"2016","unstructured":"Chou H.S.; Larsson M.; Hsiao M.H.; Chen Y.C.; R\u00f6ding M.; Nyd\u00e9n M.; Liu D.M.; Injectable insulin-lysozyme-loaded nanogels with enzymatically-controlled degradation and release for basal insulin treatment: In vitro characterization and in vivo observation. J Control Release  2016,224,33-42","journal-title":"J Control Release"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jconrel.2016.04.012","volume":"232","author":"Lopes M.","year":"2016","unstructured":"Lopes M.; Shrestha N.; Correia A.; Shahbazi M.A.; Sarmento B.; Hirvonen J.; Veiga F.; Sei\u00e7a R.; Ribeiro A.; Santos H.A.; Dual chitosan\/albumin-coated alginate\/dextran sulfate nanoparticles for enhanced oral delivery of insulin. J Control Release  2016,232,29-41","journal-title":"J Control Release"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1700413","DOI":"10.1002\/marc.201700413","volume":"38","author":"Xie J.","year":"2017","unstructured":"Xie J.; Li A.; Li J.; Advances in pH\u2010Sensitive Polymers for Smart Insulin Delivery. Macromol Rapid Commun  2017,38(23),1700413","journal-title":"Macromol Rapid Commun"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1358\/dot.2006.42.6.985632","volume":"42","author":"Cernea S.","year":"2006","unstructured":"Cernea S.; Raz I.; Noninjectable methods of insulin administration. Drugs Today (Barc)  2006,42(6),405-424","journal-title":"Drugs Today (Barc)"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3390\/polym11091380","volume":"11","author":"Mansoor S.","year":"2019","unstructured":"Mansoor S.; Kondiah P.P.D.; Choonara Y.E.; Pillay V.; Polymer-Based Nanoparticle Strategies for Insulin Delivery. Polymers (Basel)  2019,11(9),1380","journal-title":"Polymers (Basel)"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1615\/JEnvironPatholToxicolOncol.2017020182","volume":"36","author":"Chellappan D.K.","year":"2017","unstructured":"Chellappan D.K.; Yenese Y.; Wei C.C.; Chellian J.; Gupta G.; Oral Insulin: Current status, challenges, and future perspectives. J Environ Pathol Toxicol Oncol  2017,36(4),283-291","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"9949","DOI":"10.1038\/s41598-022-13092-6","volume":"12","author":"Guo Y.","year":"2022","unstructured":"Guo Y.; Baldelli A.; Singh A.; Fathordoobady F.; Kitts D.; Pratap-Singh A.; Production of high loading insulin nanoparticles suitable for oral delivery by spray drying and freeze drying techniques. Sci Rep  2022,12(1),9949","journal-title":"Sci Rep"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/jama.2015.2928","volume":"313","author":"Bonifacio E.","year":"2015","unstructured":"Bonifacio E.; Ziegler A.G.; Klingensmith G.; Schober E.; Bingley P.J.; Rottenkolber M.; Theil A.; Eugster A.; Puff R.; Peplow C.; Buettner F.; Lange K.; Hasford J.; Achenbach P.; Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: The Pre-POINT randomized clinical trial. JAMA  2015,313(15),1541-1549","journal-title":"JAMA"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1111\/dom.14499","volume":"23","author":"Eldor R.","year":"2021","unstructured":"Eldor R.; Neutel J.; Homer K.; Kidron M.; Efficacy and safety of 28\u2010day treatment with oral insulin (ORMD \u20100801) in patients with type 2 diabetes: A randomized, placebo\u2010controlled trial. Diabetes Obes Metab  2021,23(11),2529-2538","journal-title":"Diabetes Obes Metab"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"e59524","DOI":"10.1371\/journal.pone.0059524","volume":"8","author":"Eldor R.","year":"2013","unstructured":"Eldor R.; Arbit E.; Corcos A.; Kidron M.; Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: A pilot study. PLoS One  2013,8(4),e59524","journal-title":"PLoS One"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa012350","volume":"346","year":"2002","unstructured":"Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med  2002,346(22),1685-1691","journal-title":"N Engl J Med"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1001\/jama.2017.17070","volume":"318","author":"Krischer J.P.","year":"2017","unstructured":"Krischer J.P.; Schatz D.A.; Bundy B.; Skyler J.S.; Greenbaum C.J.; Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes. JAMA  2017,318(19),1891-1902","journal-title":"JAMA"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1463-1326.2009.01146.x","volume":"12","author":"Luzio S.D.","year":"2010","unstructured":"Luzio S.D.; Dunseath G.; Lockett A.; Broke-Smith T.P.; New R.R.; Owens D.R.; The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes Obes Metab  2010,12(1),82-87","journal-title":"Diabetes Obes Metab"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/s41591-019-0598-9","volume":"25","author":"Abramson A.","year":"2019","unstructured":"Abramson A.; Caffarel-Salvador E.; Soares V.; Minahan D.; Tian R.Y.; Lu X.; Dellal D.; Gao Y.; Kim S.; Wainer J.; Collins J.; Tamang S.; Hayward A.; Yoshitake T.; Lee H.C.; Fujimoto J.; Fels J.; Frederiksen M.R.; Rahbek U.; Roxhed N.; Langer R.; Traverso G.; A luminal unfolding microneedle injector for oral delivery of macromolecules. Nat Med  2019,25(10),1512-1518","journal-title":"Nat Med"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.2147\/DDDT.S79322","volume":"9","author":"Matteucci E.","year":"2015","unstructured":"Matteucci E.; Giampietro O.; Covolan V.; Giustarini D.; Fanti P.; Rossi R.; Insulin administration: Present strategies and future directions for a noninvasive (possibly more physiological) delivery. Drug Des Devel Ther  2015,9,3109-3118","journal-title":"Drug Des Devel Ther"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.addr.2018.12.006","volume":"139","author":"Zhang Y.","year":"2019","unstructured":"Zhang Y.; Yu J.; Kahkoska A.R.; Wang J.; Buse J.B.; Gu Z.; Advances in transdermal insulin delivery. Adv Drug Deliv Rev  2019,139,51-70","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.2174\/1389450119666180523092100","volume":"19","author":"Pandey M.","year":"2018","unstructured":"Pandey M.; Choudhury H.; Yi C.X.; Mun C.W.; Phing G.K.; Rou G.X.; Singh B.J.K.A.P.A.J.; Jhee A.N.A.; Chin L.K.; Kesharwani P.; Gorain B.; Hussain Z.; Recent updates on novel approaches in insulin drug delivery: A review of challenges and pharmaceutical implications. Curr Drug Targets  2018,19(15),1782-1800","journal-title":"Curr Drug Targets"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1185\/030079906X132712","volume":"22","author":"Fabbri L.","year":"2006","unstructured":"Fabbri L.; Pulmonary safety of inhaled insulins: A review of the current data. Curr Med Res Opin  2006,22,S21-S28","journal-title":"Curr Med Res Opin"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"180","DOI":"10.2337\/diaspect.29.3.180","volume":"29","author":"Oleck J.","year":"2016","unstructured":"Oleck J.; Kassam S.; Goldman J.D.; Commentary: Why was inhaled insulin a failure in the market? Diabetes Spectr  2016,29(3),180-184","journal-title":"Diabetes Spectr"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1517\/17425247.2015.990436","volume":"12","author":"Rashid J.","year":"2015","unstructured":"Rashid J.; Absar S.; Nahar K.; Gupta N.; Ahsan F.; Newer devices and improved formulations of inhaled insulin. Expert Opin Drug Deliv  2015,12(6),917-928","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1023\/A:1008786600530","volume":"22","author":"Le Brun P.P.H.","year":"2000","unstructured":"Le Brun P.P.H.; de Boer A.H.; Frijlink H.W.; Heijerman H.G.M.; A review of the technical aspects of drug nebulization. Pharm World Sci  2000,22(3),75-81","journal-title":"Pharm World Sci"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1177\/1932296814555820","volume":"8","author":"Klonoff D.C.","year":"2014","unstructured":"Klonoff D.C.; Afrezza inhaled insulin: The fastest-acting FDA-approved insulin on the market has favorable properties. J Diabetes Sci Technol  2014,8(6),1071-1073","journal-title":"J Diabetes Sci Technol"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1089\/dia.2017.0463","volume":"20","author":"Pettus J.","year":"2018","unstructured":"Pettus J.; Santos Cavaiola T.; Edelman S.V.; Recommendations for Initiating Use of Afrezza Inhaled Insulin in Individuals with Type 1 Diabetes. Diabetes Technol Ther  2018,20(6),448-451","journal-title":"Diabetes Technol Ther"},{"key":"ref=157","first-page":"735","volume":"40","author":"Goldberg T.","year":"2015","unstructured":"Goldberg T.; Wong E.; Afrezza (Insulin Human) Inhalation Powder: A New Inhaled Insulin for the Management Of Type-1 or Type-2 Diabetes Mellitus. PandT  2015,40(11),735-741","journal-title":"PandT"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2165\/11536700-000000000-00000","volume":"24","author":"Neumiller J.J.","year":"2010","unstructured":"Neumiller J.J.; Campbell R.K.; Technosphere\u00ae Insulin. BioDrugs  2010,24(3),165-172","journal-title":"BioDrugs"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1463-1326.2011.01500.x","volume":"14","author":"Raskin P.","year":"2012","unstructured":"Raskin P.; Heller S.; Honka M.; Chang P.C.; Boss A.H.; Richardson P.C.; Amin N.; Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: A randomized trial. Diabetes Obes Metab  2012,14(2),163-173","journal-title":"Diabetes Obes Metab"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.2337\/dc15-0075","volume":"38","author":"Bode B.W.","year":"2015","unstructured":"Bode B.W.; McGill J.B.; Lorber D.L.; Gross J.L.; Chang P.C.; Bregman D.B.; Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: A randomized 24-week trial. Diabetes Care  2015,38(12),2266-2273","journal-title":"Diabetes Care"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1007\/s11095-017-2215-2","volume":"34","author":"Fink J.B.","year":"2017","unstructured":"Fink J.B.; Molloy L.; Patton J.S.; Galindo-Filho V.C.; de Melo Barcelar J.; Alcoforado L.; Brand\u00e3o S.C.S.; de Andrade A.D.; Good things in small packages: An innovative delivery approach for inhaled insulin. Pharm Res  2017,34(12),2568-2578","journal-title":"Pharm Res"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1463-1326.2008.00961.x","volume":"11","author":"Heise T.","year":"2009","unstructured":"Heise T.; Brugger A.; Cook C.; Eckers U.; Hutchcraft A.; Nosek L.; Rave K.; Troeger J.; Valaitis P.; White S.; Heinemann L.; PROMAXX \u00ae inhaled insulin: Safe and efficacious administration with a commercially available dry powder inhaler. Diabetes Obes Metab  2009,11(5),455-459","journal-title":"Diabetes Obes Metab"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/j.1464-5491.2004.01240.x","volume":"21","author":"Rave K.","year":"2004","unstructured":"Rave K.; Nosek L.; Heinemann L.; Gonzales C.; Ernest C.S.; Chien J.; Muchmore D.; Inhaled micronized crystalline human insulin using a dry powder inhaler: Dose\u2010response and time\u2010action profiles. Diabet Med  2004,21(7),763-768","journal-title":"Diabet Med"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.2146\/ajhp040249","volume":"62","author":"Mandal T.K.","year":"2005","unstructured":"Mandal T.K.; Inhaled insulin for diabetes mellitus. Am J Health Syst Pharm  2005,62(13),1359-1364","journal-title":"Am J Health Syst Pharm"},{"key":"ref=165","volume":"1","author":"Aiman Ahmad I.O.","year":"2014","unstructured":"Aiman Ahmad I.O.; Anuar Zaini Md Zain and Ezharul Hoque Chowdhury. Recent Advances in Insulin Therapy for Diabetes. Int J Diabetes Clin Res  2014,1(1)","journal-title":"Int J Diabetes Clin Res"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.drudis.2018.11.010","volume":"24","author":"Easa N.","year":"2019","unstructured":"Easa N.; Alany R.G.; Carew M.; Vangala A.; A review of non-invasive insulin delivery systems for diabetes therapy in clinical trials over the past decade. Drug Discov Today  2019,24(2),440-451","journal-title":"Drug Discov Today"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1089\/dia.2019.0374","volume":"22","author":"Aanstoot H.J.","year":"2020","unstructured":"Aanstoot H.J.; Rodriguez H.; Weinzimer S.; Vint N.; Koeneman L.; Precision Dosing of Rapid-Acting Insulin Matters. Diabetes Technol Ther  2020,22(5),346-351","journal-title":"Diabetes Technol Ther"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/dom.12689","volume":"18","author":"Khunti K.","year":"2016","unstructured":"Khunti K.; Alsifri S.; Aronson R.; Cigrovski Berkovi\u0107 M.; Enters-Weijnen C.; Fors\u00e9n T.; Galstyan G.; Geelhoed-Duijvestijn P.; Goldfracht M.; Gydesen H.; Kapur R.; Lalic N.; Ludvik B.; Moberg E.; Pedersen-Bjergaard U.; Ramachandran A.; Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin\u2010treated type 1 and type 2 diabetes: The global HAT study. Diabetes Obes Metab  2016,18(9),907-915","journal-title":"Diabetes Obes Metab"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S1262-3636(07)70160-X","volume":"31","author":"Gin H.","year":"2005","unstructured":"Gin H.; Hanaire-Broutin H.; Reproducibility and variability in the action of injected insulin. Diabetes Metab  2005,31(1),7-13","journal-title":"Diabetes Metab"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1210\/jc.2013-1589","volume":"98","author":"Weinstock R.S.","year":"2013","unstructured":"Weinstock R.S.; Xing D.; Maahs D.M.; Michels A.; Rickels M.R.; Peters A.L.; Bergenstal R.M.; Harris B.; DuBose S.N.; Miller K.M.; Beck R.W.; Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: Results from the T1D Exchange clinic registry. J Clin Endocrinol Metab  2013,98(8),3411-3419","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/nu10010109","volume":"10","author":"Tascini G.","year":"2018","unstructured":"Tascini G.; Berioli M.; Cerquiglini L.; Santi E.; Mancini G.; Rogari F.; Toni G.; Esposito S.; Carbohydrate Counting in Children and Adolescents with Type 1 Diabetes. Nutrients  2018,10(1),109","journal-title":"Nutrients"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s13300-019-0574-x","volume":"10","author":"Bahendeka S.","year":"2019","unstructured":"Bahendeka S.; Kaushik R.; Swai A.B.; Otieno F.; Bajaj S.; Kalra S.; Bavuma C.M.; Karigire C.; EADSG Guidelines: Insulin Storage and Optimisation of Injection Technique in Diabetes Management. Diabetes Ther  2019,10(2),341-366","journal-title":"Diabetes Ther"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1055\/a-1010-5466","volume":"129","author":"Kongmalai T.","year":"2021","unstructured":"Kongmalai T.; Preechasuk L.; Junnu S.; Manocheewa S.; Srisawat C.; Sriwijitkamol A.; The Effect of Temperature on the Stability of In-Use Insulin Pens. Exp Clin Endocrinol Diabetes  2021,129(9),683-688","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0731-7085(89)80082-2","volume":"7","author":"Farid N.A.","year":"1989","unstructured":"Farid N.A.; Atkins L.M.; Becker G.W.; Dinner A.; Heiney R.E.; Miner D.J.; Riggin R.M.; Liquid chromatographic control of the identity, purity and \u201cpotency\u201d of biomolecules used as drugs. J Pharm Biomed Anal  1989,7(2),185-188","journal-title":"J Pharm Biomed Anal"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"13656","DOI":"10.1038\/s41598-020-70376-5","volume":"10","author":"Arpaia P.","year":"2020","unstructured":"Arpaia P.; Cesaro U.; Frosolone M.; Moccaldi N.; Taglialatela M.; A micro-bioimpedance meter for monitoring insulin bioavailability in personalized diabetes therapy. Sci Rep  2020,10(1),13656","journal-title":"Sci Rep"},{"key":"ref=176","first-page":"393","volume":"322","author":"Voelker R.","year":"2019","unstructured":"Voelker R.; Insulin Pumps Could Be Hacked. JAMA  2019,322(5),393","journal-title":"JAMA"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"827484","DOI":"10.3389\/fendo.2022.827484","volume":"13","author":"Masierek M.","year":"2022","unstructured":"Masierek M.; Nabrdalik K.; Janota O.; Kwiendacz H.; Macherski M.; Gumprecht J.; The Review of Insulin Pens\u2014Past, Present, and Look to the Future. Front Endocrinol (Lausanne)  2022,13,827484","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1038\/s41598-019-41430-8","volume":"9","author":"Lee S.H.","year":"2019","unstructured":"Lee S.H.; Ahn J.W.; Cho Y.C.; Kim S.N.; Lee C.; Ku G.W.; Bin Choy Y.; Kim H.C.; Wirelessly Controlled Implantable System for On-demand and Pulsatile Insulin Administration. Sci Rep  2019,9(1),5009","journal-title":"Sci Rep"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1602494","volume":"375","author":"Stewart Z.A.","year":"2016","unstructured":"Stewart Z.A.; Wilinska M.E.; Hartnell S.; Temple R.C.; Rayman G.; Stanley K.P.; Simmons D.; Law G.R.; Scott E.M.; Hovorka R.; Murphy H.R.; Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. N Engl J Med  2016,375(7),644-654","journal-title":"N Engl J Med"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa1509351","volume":"373","author":"Thabit H.","year":"2015","unstructured":"Thabit H.; Tauschmann M.; Allen J.M.; Leelarathna L.; Hartnell S.; Wilinska M.E.; Acerini C.L.; Dellweg S.; Benesch C.; Heinemann L.; Mader J.K.; Holzer M.; Kojzar H.; Exall J.; Yong J.; Pichierri J.; Barnard K.D.; Kollman C.; Cheng P.; Hindmarsh P.C.; Campbell F.M.; Arnolds S.; Pieber T.R.; Evans M.L.; Dunger D.B.; Hovorka R.; Home Use of an Artificial Beta Cell in Type 1 Diabetes. N Engl J Med  2015,373(22),2129-2140","journal-title":"N Engl J Med"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1111\/dom.14815","volume":"24","author":"Hood K.K.","year":"2022","unstructured":"Hood K.K.; Garcia-Willingham N.; Hanes S.; Tanenbaum M.L.; Ware J.; Boughton C.K.; Allen J.M.; Wilinska M.E.; Tauschmann M.; Denvir L.; Thankamony A.; Campbell F.; Wadwa R.P.; Buckingham B.A.; Davis N.; DiMeglio L.A.; Mauras N.; Besser R.E.J.; Ghatak A.; Weinzimer S.A.; Fox D.S.; Kanapka L.; Kollman C.; Sibayan J.; Beck R.W.; Hovorka R.; Lived experience of CAMAPS FX closed loop system in youth with type 1 diabetes and their parents. Diabetes Obes Metab  2022,24(12),2309-2318","journal-title":"Diabetes Obes Metab"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"114280","DOI":"10.1016\/j.addr.2022.114280","volume":"185","author":"Domingo-Lopez D.A.","year":"2022","unstructured":"Domingo-Lopez D.A.; Lattanzi G.; H J Schreiber L.; Wallace E.J.; Wylie R.; O\u2019Sullivan J.; Dolan E.B.; Duffy G.P.; Medical devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus. Adv Drug Deliv Rev  2022,185,114280","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/1932296818814541","volume":"13","author":"Thompson B.","year":"2019","unstructured":"Thompson B.; Cook C.B.; Insulin Pumping Patches: Emerging Insulin Delivery Systems. J Diabetes Sci Technol  2019,13(1),8-10","journal-title":"J Diabetes Sci Technol"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/14782715221088981","volume":"52","author":"Kishor Sharma J.","year":"2022","unstructured":"Kishor Sharma J.; Sharma D.; Gupta A.; A glorious past, dynamic present and a promising future: Insulin at 100. J R Coll Phys Edinb  2022,52(1),59-64","journal-title":"J R Coll Phys Edinb"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0140-6736(20)32514-9","volume":"397","author":"Bergenstal R.M.","year":"2021","unstructured":"Bergenstal R.M.; Nimri R.; Beck R.W.; Criego A.; Laffel L.; Schatz D.; Battelino T.; Danne T.; Weinzimer S.A.; Sibayan J.; Johnson M.L.; Bailey R.J.; Calhoun P.; Carlson A.; Isganaitis E.; Bello R.; Albanese-O\u2019Neill A.; Dovc K.; Biester T.; Weyman K.; Hood K.; Phillip M.; A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): A multicentre, randomised, crossover trial. Lancet  2021,397(10270),208-219","journal-title":"Lancet"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"e14863","DOI":"10.1111\/dme.14863","volume":"39","author":"Ng S.M.","year":"2022","unstructured":"Ng S.M.; Katkat N.; Day H.; Hubbard R.; Quinn M.; Finnigan L.; Real\u2010world prospective observational single\u2010centre study: Hybrid closed loop improves HbA1c, time\u2010in\u2010range and quality of life for children, young people and their carers. Diabet Med  2022,39(7),e14863","journal-title":"Diabet Med"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"e15015","DOI":"10.1111\/dme.15015","volume":"40","author":"Ng S.M.","year":"2023","unstructured":"Ng S.M.; Wright N.P.; Yardley D.; Campbell F.; Randell T.; Trevelyan N.; Ghatak A.; Hindmarsh P.C.; Real world use of hybrid\u2010closed loop in children and young people with type 1 diabetes mellitus\u2014a National Health Service pilot initiative in England. Diabet Med  2023,40(2),e15015","journal-title":"Diabet Med"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.ijbiomac.2021.05.052","volume":"181","author":"Akbarian M.","year":"2021","unstructured":"Akbarian M.; Insulin therapy; a valuable legacy and its future perspective. Int J Biol Macromol  2021,181,1224-1230","journal-title":"Int J Biol Macromol"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010287216240324050651","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/228531\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010287216240324050651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:42:04Z","timestamp":1747741324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/228531\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":188,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892010287216240324050651","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}